HomeCompareCHSYF vs EQR

CHSYF vs EQR: Dividend Comparison 2026

CHSYF yields 2.81% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $26.6K in total portfolio value
10 years
CHSYF
CHSYF
● Live price
2.81%
Share price
$1.35
Annual div
$0.04
5Y div CAGR
-21.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.2K
Annual income
$27.60
Full CHSYF calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — CHSYF vs EQR

📍 EQR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHSYFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHSYF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CHSYF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHSYF
Annual income on $10K today (after 15% tax)
$239.26/yr
After 10yr DRIP, annual income (after tax)
$23.46/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, EQR beats the other by $4,630.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHSYF + EQR for your $10,000?

CHSYF: 50%EQR: 50%
100% EQR50/50100% CHSYF
Portfolio after 10yr
$34.5K
Annual income
$2,751.60/yr
Blended yield
7.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

CHSYF
No analyst data
Altman Z
10.1
Piotroski
5/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHSYF buys
0
EQR buys
0
No recent congressional trades found for CHSYF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHSYFEQR
Forward yield2.81%5.87%
Annual dividend / share$0.04$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-21.3%15.8%
Portfolio after 10y$21.2K$47.8K
Annual income after 10y$27.60$5,475.61
Total dividends collected$979.00$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CHSYF vs EQR ($10,000, DRIP)

YearCHSYF PortfolioCHSYF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$10,922$221.53$11,380$679.82$458.00EQR
2$11,864$177.95$13,014$837.25$1.1KEQR
3$12,837$142.18$14,961$1,036.20$2.1KEQR
4$13,848$113.15$17,297$1,289.22$3.4KEQR
5$14,908$89.78$20,121$1,613.15$5.2KEQR
6$16,022$71.09$23,561$2,030.84$7.5KEQR
7$17,200$56.19$27,783$2,573.54$10.6KEQR
8$18,448$44.37$33,013$3,284.39$14.6KEQR
9$19,775$35.00$39,547$4,223.51$19.8KEQR
10$21,186$27.60$47,791$5,475.61$26.6KEQR

CHSYF vs EQR: Complete Analysis 2026

CHSYFStock

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications. In addition, the company also offers Elcatonin injection for osteoporosis; YinlianQinggan granules for treating acute hepatitis A and chronic hepatitis B; Lamisil tablets for treating fungal infections on skin and hair; and MOVICOL for treating chronic constipation and faecal impaction. In addition, it is involved in the agriculture and livestock activities. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.

Full CHSYF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this CHSYF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHSYF vs SCHDCHSYF vs JEPICHSYF vs OCHSYF vs KOCHSYF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.